Blueprint Medicines Corporation
BPMC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.94 | 1.05 | 0.31 | 0.03 |
| FCF Yield | -3.60% | -8.11% | -19.56% | -8.93% |
| EV / EBITDA | 304.12 | -13.37 | -5.31 | -9.82 |
| Quality | ||||
| ROIC | -22.43% | -53.20% | -46.43% | -58.24% |
| Gross Margin | 96.04% | 94.87% | 91.27% | 90.04% |
| Cash Conversion Ratio | 2.87 | 0.86 | 0.90 | 0.46 |
| Growth | ||||
| Revenue 3-Year CAGR | 35.61% | 11.46% | -36.42% | 39.38% |
| Free Cash Flow Growth | 56.46% | 11.40% | 8.70% | -245.85% |
| Safety | ||||
| Net Debt / EBITDA | 19.09 | -1.49 | -0.24 | 0.16 |
| Interest Coverage | -3.08 | -9.42 | -32.76 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 1.48 | 0.60 | 0.60 | 0.82 |
| Cash Conversion Cycle | 179.15 | 534.22 | 618.67 | 349.49 |